Secretin
Pancreatic Ductal Adenocarcinoma
Adenocyte, LLCprotein_peptideActive
D
28/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 65/ 100
Competitive context
148 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Jonsson Comprehensive Cancer Center | Phase 4 | BB |
FLUOROURACILUM Jonsson Comprehensive Cancer Center | Phase 3 | B |
Capecitabine Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 3 | B |
Calcium folinate pentahydrate Jonsson Comprehensive Cancer Center | Phase 3 | B |
Cyclophosphamide Beijing Biotech | Phase 2 | B |
View all 50 →
Same molecule, other indications
Secretin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →